Sola
is Rising:
Next-Gen IVL
for Coronary Artery Disease
Unparalleled Deliverability
Target the most challenging coronary lesions with the low-profile actuating emitter in Sola™, specifically designed to facilitate exceptional crossability.
Untethered Energy
Sola™ is designed for the most challenging procedures, offering significantly more therapeutic pulses at considerably faster rates.
360° Energy Output
With Sola™, every energy pulse is engineered to deliver circumferential sonic pressure to any lesion, providing predictable, multi-directional performance.
Coronary Pre-Clinical Evidence
Pre-Treatment
Post-Treatment
Deep Calcium Fissures
Our novel coronary system has demonstrated impressive efficacy in cadaveric artery disease models, leading to compelling luminal gain through comprehensive calcium fracturing.
Post-Treatment
Omni-Directional Calcium Cracking
FastWave’s next-gen coronary platform delivers consistent and powerful 360-degree energy, resulting in multi-directional fractures for optimal vessel expansion.
Future Studies
Coronary IDE Trial
We anticipate IDE approval from FDA to begin a coronary IDE trial in early 2026. This study will evaluate the safety and efficacy of our coronary IVL system in treating patients with calcified coronary arterial disease.
